Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults

Canadian Respiratory Journal

Volumn 11, Issue 8, 2004, Pages 589-593

  Weiss, K ^a   Low, D E ^b   Cortes, L ^a   Beaupre, A ^a   Gauthier, R ^a   Gregoire, P ^a   Legare, M ^a   Nepveu, F ^a   Thibert, D ^a   Tremblay, C ^a   Tremblay, J ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bacteremia; Pneumonia; Streptococcus pneumoniae

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; MACROLIDE; PENICILLIN G;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLOOD PRESSURE MEASUREMENT; BREATHING RATE; CLINICAL FEATURE; COHORT ANALYSIS; COLITIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; EATING; FEMALE; FEVER; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STANDARDIZATION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 19944429796     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/461392     Document Type: Article

References (30)

1. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH; The Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infec Dis 2000;31:383-421.
2. Marrie TJ. Community-acquired pneumonia. Clin Infect Dis 1994;18:501-13.
3. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Eng J Med 1995;333:1618-24.
4. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275:134-41.
5. Austriam R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964;60:759-76.
6. Torres JM, Cardenas O, Vasquez A, Schlossberg D. Streptococcus pneumoniae bacteremia in a community hospital. Chest 1998;113:387-90.
7. Bartlett JG, Breiman RF, Mandell LA, File TM Jr, for the Infectious Diseases Society of America. Community-acquired pneumonia in adults: Guidelines for management. Clin Infect Dis 1998;26:811-38.
8. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 2001:56(Suppl 4):IV1-64.
9. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;161:1837-42.
10. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36:389-95.
11. Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: A one year prospective study of 346 consecutive patients. Thorax 1996;51:179-84.
12. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;35:556-64.
13. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-50.
14. Weiss K, Restieri C, Gauthier R, et al. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis 2001;33:517-22.
15. Chow AW, Hall CB, Klein JO, Kammer RB, Meyer RD, Remington JS, for the Infectious Diseases Society of America and the Food and Drug Administration. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Clin Infect Dis 1992;15(Suppl 1):S62-88.
16. Weiss K, de Azavedo J, Restieri C, et al. In vitro activity of a novel ketolide ABT-773 against invasive strains of Streptococcus pneumoniae. J Antimicrob Chemother 2001;48:407-9.
17. National Committee for Clinical Laboratory Standards. Methods for Dilution, Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 7th edn. Approved standard M2-A7. Villanova: National Committee for Clinical Laboratory Standards, 2000.
18. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
19. Watanakunakorn C, Bailey TA. Adult bacteremic pneumoccoccal pneumonia in a community teaching hospital, 1992-1996: A detailed analysis of 108 cases. Arch Intern Med 1997;157:1965-71.
20. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Internal Med 1999;159:2562-72
21. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080-4
22. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997;156:266-71.
23. Kaul R, McGeer A, Norrhy-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - A comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999;28:800-7.
24. Gillespie SH. Antibiotic resistance in the absence of selective prssure. Int J Antimicrob Agents 2000;17:171-6.
25. Moroney JF, Fiore AE, Harrison LH, et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001;33:797-805.
26. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000;283:749-55.
27. Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 2001;119:1439-48.
28. Pelton SI, Dagan R, Gaines BM, et al. Pneumococcal conjugate vaccines: Proceedings from an interactive symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Vaccine 2003;21:1562-71.
29. Zhang Y, Isaacman DJ, Wadowsky RM, Rydquist-White J, Post JC, Ehrlich GD. Detection of Streptococcus pneumoniae in whole blood by PCR. J Clin Microbiol 1995;33:596-601.
30. Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001;39:3495-8.